Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway
Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo and the second study reaching 168% relative improvement to placebo Positive safety profile demonstrated
Healthcare and Hospitals, Health
2025-12-03 1:12 AM EST | Cosmo Pharmaceuticals N.V.
Envoy Medical Announces the Grant of Its 40th U.S. Patent
White Bear Lake, Minnesota--(Newsfile Corp. - December 2, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received its 40th active U.S. Patent from the United States Patent and Trademark Office. The new patent further strengthens the Company's intellectual property portfolio, which includes an additional 45 issued foreign patents. U.S. Paten
Biotechnology, Healthcare and Hospitals
2025-12-02 8:00 AM EST | Envoy Medical, Inc.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, announces the completion of its previously disclosed debt settlement from November 21, 2025. The Company issued 34,540 common shares (each, a "Share") at $0.74 per Share to settle $25,560 of debt
Technology, Healthcare and Hospitals, Health
2025-12-01 6:15 PM EST | FendX Technologies Inc.
Adia Med Partners with America's #1 Health Talk Show Host, Dr. Asa Andrew, to Bring Breakthrough Stem Cell Therapies to the Spotlight
Winter Park, Florida--(Newsfile Corp. - December 1, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), one of the nation's leaders in Stem Cell Technology is excited to announce a partnership with 3X Physician and Multi-Platform Media talk show personality Dr. Asa Andrew (known to his fans as Doctor Asa).
Healthcare and Hospitals, Health
2025-12-01 9:30 AM EST | Adia Nutrition Inc.
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its research partners from the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-UL) were awarded the Innovation Award from Industrial Research Cluster during the 35th annual ADRIQ
Technology, Biotechnology, Healthcare and Hospitals
2025-12-01 8:30 AM EST | BioMark Diagnostics, Inc.
Senior Care Authority Highlights Urgent Need for Proactive Driving-Safety Conversations as Older Driver Awareness Week Begins
Incline Village, Nevada--(Newsfile Corp. - December 1, 2025) - Today marks the start of Older Driver Awareness Week, Dec. 1-5, and Senior Care Authority, a national eldercare consulting and senior living placement company, is encouraging families to begin proactive conversations about driving safety with aging loved ones before a crisis forces the issue. According to
Healthcare and Hospitals, Health
2025-12-01 8:00 AM EST | Senior Care Authority
MyndTec Inc. Announces Resignation of Director
Mississauga, Ontario--(Newsfile Corp. - November 26, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, today announced that P. Harvey Griggs has resigned from the Company's Board of Directors, effective November 26, 2025, for personal reasons to focus on his health. Dr. Griggs served as a director of MyndTec for six years and was an early investor in the Company. "On behalf of the Boa
Technology, Healthcare and Hospitals, Health
2025-11-26 5:30 PM EST | MyndTec Inc.
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth co
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-25 11:30 AM EST | Phio Pharmaceuticals Corp.
ADIA Nutrition Submits Patent-Pending Autism Protocol for Independent IRB Review - Clinical Study Launch Nears
Winter Park, Florida--(Newsfile Corp. - November 24, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) announced today that, following the independent Institutional Review Board's (IRB) acceptance of its initial draft protocol and invitation to submit a final version, the company has now officially delivered the complete, Patent-Pending regenerative protocol for pediatric Autism Spectrum Disorder (ASD) for full review and potential acceptance of oversight. This submission represents a pivotal
Healthcare and Hospitals, Health
2025-11-24 8:00 AM EST | Adia Nutrition Inc.
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed a U.S. Food and Drug Administration (FDA) Type C meeting in September; FDA confirmed that multiple regulatory routes are available to support approval of NVG-291 as the first pharmacologic treatment for spinal cord injury Completed a US$1
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-24 7:05 AM EST | NervGen Pharma Corp.
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo Participant-reported outcomes highlight substantial improvements in bladder control and muscle spasticity compared to placebo Statistically significant reduction of hyperactive reticulospinal signaling in upper and lower limbs
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-24 7:00 AM EST | NervGen Pharma Corp.
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC") as the sole agent and bookrunner on a commercially re
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-24 7:00 AM EST | Theralase Technologies Inc.
FendX Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it intends to settle outstanding debts totalling approximately $25,560 owed by the Company to two arms-length consultants for services performed and payable in common share
Technology, Healthcare and Hospitals, Health
2025-11-21 6:00 PM EST | FendX Technologies Inc.
Discovery Senior Living Names New SVP, A Proven Sales Leader Reinforcing Industry-Leading Sales Infrastructure
Bonita Springs, Florida--(Newsfile Corp. - November 21, 2025) - Discovery Senior Living ("Discovery" or the "Company") and its affiliated subsidiaries, one of the most trusted and the largest privately held senior housing operators in the U.S., is pleased to announce Brennan Hughes as Senior Vice President of Sales, effective immediately. With more than 20 years of sales leadership, Brennan brings deep experience in scaling national sales organizations and driving performance and
Healthcare and Hospitals, Real Estate, Housing
2025-11-21 2:16 PM EST | Discovery Senior Living
LevelJump Sets Date for Requisitioned Shareholder Meeting
Toronto, Ontario--(Newsfile Corp. - November 20, 2025) - Further to its news release of November 7, 2025, LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") announces that its board of directors (the "Board") has called an annual and special meeting of shareholders (the "Meeting") to be held on May 26th, 2026 in response to a shareholder requisition (the "Requisition") submitted by Frank Teti and Franmar Properties Ltd. (collectively the "Concerned Shareholders"
Healthcare and Hospitals, Health
2025-11-20 4:15 PM EST | LevelJump Healthcare Corp.
Conexeu Sciences Signals a Major Breakthrough in 'Personalized Human Tissue Creation'
Reno, Nevada--(Newsfile Corp. - November 20, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, is pleased to announce that it has achieved a defining milestone in regenerative medicine with the first ever 3D-printed structures made entirely from its patented, functional extracellular matrix (ECM). Using its patented CXU™ platform, the Company has printed bovine-derived
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-20 9:00 AM EST | Conexeu Sciences Inc.
Envoy Medical Secures New U.S. Patent for Innovative Cochlear Implant System Featuring a Removable Earplug Sensor and an Implanted Battery
White Bear Lake, Minnesota--(Newsfile Corp. - November 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of U.S. Patent No. 12,465,754, granted by the United States Patent and Trademark Office (USPTO) on November 11, 2025. The patent, titled "Combination Implant System with Removable Earplug Sensor and Implanted Battery," repre
Biotechnology, Healthcare and Hospitals
2025-11-20 8:00 AM EST | Envoy Medical, Inc.
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its common shares (TSX: MDP). Under the NCIB, Medexus may purchase for cancellation up to 2,983,650 common shares, representing approximately 10% of the public float as defined under TSX rules. As of November 12, 2025, 32
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-20 7:30 AM EST | Medexus Pharmaceuticals Inc.
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has completed its previously announced non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other acc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-19 4:26 PM EST | NervGen Pharma Corp.
Discovery Senior Living Ranked #1 in the Nation for Customer Satisfaction Among Assisted Living & Memory Care Providers in J.D. Power 2025 U.S. Senior Living Satisfaction Study
Bonita Springs, Florida--(Newsfile Corp. - November 19, 2025) - Discovery Senior Living ("Discovery", or the "Company") and its affiliated management companies, one of the most trusted and the largest privately held senior housing operator of choice in the U.S., is proud to announce a landmark achievement in the J.D. Power 2025 U.S. Senior Living Satisfaction StudySM: #1 in Customer Satisfaction among Assisted Living & Memory Care Communities
Healthcare and Hospitals, Real Estate, Housing
2025-11-19 2:10 PM EST | Discovery Senior Living